Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Long-Term Deferred Tax (2017 - 2025)

Corcept Therapeutics (CORT) has disclosed Long-Term Deferred Tax for 9 consecutive years, with $168.2 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax rose 28.48% to $168.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $168.2 million through Dec 2025, up 28.48% year-over-year, with the annual reading at $168.2 million for FY2025, 28.48% up from the prior year.
  • Long-Term Deferred Tax hit $168.2 million in Q4 2025 for Corcept Therapeutics, up from $153.0 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $168.2 million in Q4 2025 to a low of $27.5 million in Q4 2021.
  • Historically, Long-Term Deferred Tax has averaged $87.6 million across 5 years, with a median of $82.7 million in 2023.
  • Biggest five-year swings in Long-Term Deferred Tax: fell 13.13% in 2021 and later surged 123.88% in 2022.
  • Year by year, Long-Term Deferred Tax stood at $27.5 million in 2021, then soared by 123.88% to $61.5 million in 2022, then skyrocketed by 47.41% to $90.6 million in 2023, then surged by 44.49% to $130.9 million in 2024, then grew by 28.48% to $168.2 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for CORT at $168.2 million in Q4 2025, $153.0 million in Q3 2025, and $162.2 million in Q2 2025.